The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...
Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Maximize Your Portfolio with Data Driven ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...
Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...
Pfizer Inc. (PFE) is my Top Pick for income-oriented investors in 2025. The past year was unkind to the pharmaceutical giant because it does not have diabetes or weight loss drugs in its portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback